Massive Bio, a US-based provider of a clinical trials platform, is rapidly expanding its presence in Asia and has engaged us to help establish its footprint in South Korea.
Oncology trials require access to highly specific patient populations, making effective identification and recruitment critical to execution. Our new client's AI-powered platform enables hospitals and oncologists to share requirements for trials and match patients with suitable clinical studies. To date, Massive Bio has matched 200,000 patients with 19,000 trials across 17 markets.
Dashboard for Massive Bio's AI-powered platform
As part of the company's Korea expansion plans, our team in Seoul will build relationships with influential hospitals, diagnostic labs and oncologists across the country.
Our objective is to understand their interest in Massive Bio's platform, to identify potential areas of collaboration and to establish partnerships that strengthen the company's ability to connect patients and trials.
Our programme also includes participation in two important industry events. We just attended the 19th Annual Meeting of the Korean Society of Medical Oncology (KSMO), where we connected with key opinion leaders on Massive Bio's behalf.
And, in November, Massive Bio will join us at the 2026 AACR-KCA Joint Conference on Precision Medicine in Cancer, where we'll boost ties with oncology stakeholders and explore potential partnerships.
Selin Kurnaz, CEO of Massive Bio, said: "South Korea is an important market in our broader Asian expansion plans because of its strong oncology ecosystem, advanced healthcare infrastructure and clinical research landscape.
"Intralink's Korea expertise and network will help us understand the market's needs, build meaningful partnerships and expand access to our platform for clinical trials."
If you'd like to discuss opportunities for your company in South Korea, get in touch with Sol Bergen-Bartel at sol.bergenbartel@intralinkgroup.com.
